Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-001724
Filing Date
2025-01-06
Accepted
2025-01-06 09:22:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9302
2 EX-99.1 ck0001673772-ex99_1.pdf EX-99.1 78179
  Complete submission text file 0000950170-25-001724.txt   118930
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Subject) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91191 | Film No.: 25509229
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O INTERTRUST FUND SERVICES (JERSEY) 44 ESPLANADE ST HELIER Y9 JE4 9WG
Business Address C/O INTERTRUST FUND SERVICES (JERSEY) 44 ESPLANADE ST HELIER Y9 JE4 9WG 44-0-1534-504343
Medicxi IV LP (Filed by) CIK: 0001929290 (see all company filings)

EIN.: 000000000 | State of Incorp.: Y9
Type: SCHEDULE 13G